Showing results (211-220 of 366) with videos related to

Sort By:
Pageof 37
JAMA Network Open|November 12, 2025
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical TrialsPasi A Jänne, David Planchard, Koichi Goto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 23, 2025
Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in SpainVilma Pacheco-Barcia, Berta Obispo, Elia Tomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 TrialBenjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.
JAMA Oncology|October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical TrialCaicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.
The Lancet. Oncology|January 5, 2016
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trialElisabeth Quoix, Hervé Lena, Gyorgy Losonczy, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
The Lancet. Oncology|March 28, 2024
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trialEgbert F Smit, Enriqueta Felip, Dipesh Uprety, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2024
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancerDavid Planchard, Jürgen Wolf, Benjamin Solomon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 13, 2024
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based ChemotherapyMirari Echepare, Beñat Picabea, Andrea Arricibita, et al.
Future Oncology (London, England)|June 12, 2023
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancerBenjamin J Solomon, Todd M Bauer, Tony S K Mok, et al.
Pageof 37